It is unclear whether the efficacy and long-term outcome of treating patients with hepatitis C virus (HCV)-positive cirrhosis with the new protease inhibitors will extend to those with Child C cirrhosis.
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SUMMARY Background
It is unclear whether the efficacy and long-term outcome of treating patients with hepatitis C virus (HCV)-positive cirrhosis with the new protease inhibitors will extend to those with Child C cirrhosis.
Aim
To assess the effectiveness of the interferon-free regimens in Child C cirrhotic patients with HCV infection.
Methods
A systematic Medline search was conducted to retrieve studies describing the treatment of Child C patients with direct-acting agents. Citations from identified studies were cross-referenced and abstracts from European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD) meetings were checked. Extracted data were evaluated using a meta-analysis to calculate a weighted response rate.
Results
Seven full-text records and two conference abstracts were retained for analysis from the 649 records identified. Data from an Italian real-life trial were also interrogated. Information on treatment outcome was available for 228 of the 240 Child C patients evaluated in the 10 trials. Overall, the weighted mean sustained virological response (SVR12) was 74.9% (95% CI: 65.6-82.4%). Neither duration of treatment (24 or 12 weeks), nor addition of ribavirin influenced these rates. The weighted SVR12 was 65.4% (95% CI: 46.8-80.2) after sofosbuvir/simeprevir, 76.0% (95% CI: 54.4-89.3%) after sofosbuvir/daclatasvir and 83.0% (95% CI: 73.4-89.6) after sofosbuvir/ledipasvir. Some studies did not provide information on the rate of post-treatment relapse or functional improvement. However, in those studies that did provide such data, a relapse was documented in 12.1% of patients and an improvement of ≥2 points on the model for end-stage liver disease (MELD) score in 61.1% of patients.
Conclusion
The improvement in MELD scores strongly suggests HCV-positive patients with Child C cirrhosis should be treated with these agents. 
INTRODUCTION
Cirrhosis encompasses a spectrum of clinical entities ranging from early (compensated) to more severe (decompensated) cirrhosis and terminal end-stage liver disease. Compensated cirrhosis is also heterogeneous with more severe forms observed when oesophageal varices, a reflection of portal hypertension, become evident. 1 Patients with hepatitis C virus(HCV)-related cirrhosis are at risk of developing life-threatening complications, such as decompensated liver disease and hepatocellular carcinoma (HCC), or may face an orthotopic liver transplant or death in cases with unmanageable, terminal disease. 2, 3 Antiviral treatment has the potential to improve long-term outcomes for patients with cirrhosis, and viral clearance is associated with histological improvement, a decreased risk of HCC, and a reduced incidence of decompensation and of liver-and non liver-related mortality. 4, 5 A sustained virological response with a positive impact on outcome in patients with HCV-related cirrhosis has been documented following therapy with peg-interferon and ribavirin. 6, 7 Initial and fragmentary information concerning a similar favourable effect following treatment with the new direct acting antivirals has been also reported. [8] [9] [10] However, previous data have been derived from the evaluation of patients with early cirrhosis, that is those in classes A and B of the Child classification. It remains unclear whether the therapeutic benefits will extend to patients treated for more advanced disease (Child C patients). Child C patients have been traditionally denied therapy with peg-interferon and ribavirin due to concerns about the safety of these regimens in patients with extreme derangements of liver function. A similar attitude is evident in studies evaluating the benefits of therapy with the new antiviral drugs, with Child C patients under-represented both in registrative clinical trials and real-worlds settings, although in most need of viral eradication. The low number of Child C patients treated so far with the new antivirals in the studies has precluded a definitive conclusion about the benefits and harms of treating this particular subgroup of patients. In order to highlight the value of therapy for patients with Child C cirrhosis in most need of a reduction in the liver impairment caused by HCV infection, this systematic review seeks to assess the effectiveness of the interferon-free regimens in clinical practice in these patients, quantitatively synthesise available evidence where possible and estimate a weighed response following treatment with the new products. Figure 1 presents the PRISMA flow diagram for the selection of studies. A total of 649 studies were identified. Studies were excluded if they were in languages other than English, did not separately report outcome data for patients with Child A, B or C cirrhosis, or referred to transplanted patients. Duplicate publications, narrative reviews and editorials were also excluded.
METHODS

Data extraction and management
All information was extracted using a standardised data abstraction form. Data retrieved included: study characteristics (whether clinical trials or interventional studies); main infecting HCV genotypes; treatment history (na€ ıve or treatment experienced); schedules of the direct acting antiviral agents administered, including dose and duration; concomitant use of ribavirin; efficacy of therapy as ascertained by a sustained virological response at 12 weeks following treatment (SVR12); change in the model for end-stage liver disease (MELD) score at 12 weeks after treatment; and safety outcomes for the longest reported treatment and follow-up period. Only data specifically referring to Child C patients were extracted from the included studies by a single author and checked by a second independent reviewer. Any disagreements were resolved through discussion.
Data synthesis
The primary efficacy outcome was SVR12 (undetectable HCV-RNA levels 12 weeks after the end of therapy).
Owing to the risk of overestimating a beneficial outcome in trials not designed specifically for patients with Child C cirrhosis undergoing antiviral therapy and including very few patients with Child C cirrhosis, separate analyses were performed for each treatment schedules, dose and duration, and for the concomitant use or not of ribavirin, whenever possible.
Statistical analyses SVR12 rates were the measure of interest in this meta-analysis. Given the small number of patients and the very low or very high numbers in some studies, the 95% confidence intervals were calculated using the Wilson score interval. 12 Subgroup analyses were carried out to explore the impact on the SVR rate of treatment duration (24 or 12 weeks), the inclusion of ribavirin in the treatment schedule and the different new drugs regimens. We used random rather than fixed-effects models to estimate pooled proportions in order to account for the heterogeneity. 13 All analyses were performed using the Comprehensive Meta-analysis software (Version 2.2061, Biostat, Englewood, NJ, USA). Figure 1 shows the PRISMA flow diagram of the literature selection process. Seven full-text records [14] [15] [16] [17] [18] [19] [20] and two conference abstracts 21, 22 were retained for analysis.
RESULTS
Additional information for one selected trial 19 was retrieved from a follow-up study of the same cohort of patients. 23 Of the nine selected studies, three were clinical trials, 14, 15, 18 and five were real-life studies with a prospective 19, 20 or a retrospective design; 16, 17, 21 the design of the ninth investigation was not explained. 22 Data from an ongoing large, prospective Italian program evaluating treatment with the new antivirals in patients with chronic HCV infection were also interrogated, 24 and information for patients with Child C cirrhosis was extracted and pooled in the final analysis. The main characteristics of patients with cirrhosis evaluated in the 10 selected studies are shown in Table 1 . The number of patients enrolled in the individual trials varied from 42 to 2037, and their median ages were generally <60 years. The majority of patients with cirrhosis were infected by HCV genotype 1, were in Child B class and presented with a mean MELD score of <15. About two-thirds of patients had failed a previous treatment course with peginterferon and ribavirin.
Information on treatment outcome was available for 228 of the 240 Child C patients evaluated in the 10 trials. The SVR12 rates described in the individual studies are shown in Figure 2 : the rates varied from low values of 50.0% and 56.3% reported in two studies 17, 18 to high values of 94.4% and 96.0% found in two other reports. 21, 24 Overall, the weighted mean SVR12 rate was 74.9% (95% CI: 65.6-82.4%) using a random effects model. Several sub-analyses were run to explore the potential impact of the different regimens administered in the selected studies; the individual results are given in Figures S1-S5 and the pooled estimates in Figure 3 .
The first sub-analysis considered the effect of the length of treatment: the weighted mean SVR12 rate was 82.3% (95% CI: 0.71-99.0) when treatment lasted for 24 weeks, and 70.9% (95% CI: 62.0-78.5) when treatment lasted for 12 weeks (Figure 3 and Figure S1 ); a trend toward a significant difference was seen (P = 0.085). The inclusion of ribavirin in the treatment schedules did not affect these rates (Figure 3 and Figure S2) : the weighted mean value was 76.4% (95% CI: 64.7-85.1) when ribavirin was added to the new antivirals, and 79.9% (95% CI: 54.9-92.9) when was not (P = 0.758). Next, we analysed the interaction between treatment length and ribavirin administration. When treatment lasted for 24 weeks, the administration of ribavirin did not affect the SVR12 rates, which were 81.7% (95% CI; 63.1-89.9) and 95.4% (95% CI: 73.5-93.4%) when ribavirin was and was not administered respectively ( Figure S3 ). When treatment lasted for 12 weeks, the weighted SVR12 rates were 73.6% (95% CI: 62.0-82.7) and 69.2% (95% CI: 47.3-83.7) respectively. No previous differences were statistically significant ( Figure S3) . Sufficient data were available to evaluate the efficacies of three different schedules of direct acting antiviral agents, although no information was available on the efficacy of ombitasvir/paritaprevir and dasabuvir in patients with Child C cirrhosis ( Figure S4 ). The regimen of sofosbuvir plus simeprevir given for 12 weeks was evaluated in four studies: 16, 17, 24, 30 The relapse rate after treatment was reported in four studies [14] [15] [16] 24 and the data are presented in Table 2: only 13 (12.1%) of the 197 patients with Child C (Table 2) : an improvement of ≥2 points at the post-treatment follow-up was documented in 63 of 103 patients (61.1%).
DISCUSSION
The efficacy, safety and long-term outcome of treatment with new direct acting antiviral agents of patients with Child C cirrhosis are unknown, as the low numbers of these patients enrolled in either registrative or post-marketing clinical trials do not allow conclusions to be drawn. This lack of information reflects concerns and fears regarding the treatment of such patients with peginterferon and ribavirin: although such a therapy has been shown to be feasible, 7 the associated severe events and worsening of hepatic decompensation 25, 26 have discouraged physicians from administering interferon-based therapies to patients with Child C. These same concerns and fears also apply to the new interferon-free regimens. While these new regimens have proved safe and effective in patients with Child A and B cirrhosis, [8] [9] [10] data describing their use in Child C patients are limited. We sought to address this lack of information by conducting a systematic review of the published literature and tried to separate the results for Child C patients from those of the entire cohort of patients with cirrhosis in each trial. We pooled the therapeutic results for 228 Child C patients, the largest collection of such patients evaluated to date. The weighted average SVR12 rate was 74.9% (95% CI: 65.6-82.4%) in the 228 patients treated with the new direct acting antiviral agents in 10 studies. Eight of the surveyed studies had a prospective design, which further validates the observed outcome data. However, we must evaluate this rate carefully because this is an unusual population, as the majority of patients were genotype 1 and previously exposed to peg-interferon plus ribavirin. Nevertheless, this remarkable SVR12 rate indicates that this particular setting of HCV-infected patients should not be denied treatment with the new therapeutic regimens.
Although of relevance to physicians caring for these patients, the average SVR rate seen in this investigation is lower than that reported in patients with Child A and B cirrhosis. We tried to explore whether the different schedules adopted in the original investigations might have impacted on the SVR rate in these patients. As indicated in Figure 3 , neither duration of treatment (whether 24 or 12 weeks), nor the addiction of ribavirin seemed to make a difference. Numerically higher SVR12 rates were seen when therapy was administered for 24 weeks (82.3% vs. 70.9%), but this difference is likely due to the fact that more patients administered 12 weeks of treatment received therapy with the less effective schedule, that is sofosbuvir in combination with simeprevir. Indeed, the individual therapeutic regimens administered to patients resulted in some variation in the SVR12 rates: 65.4% (95% CI: 46.8-80.2) in patients treated with sofosbuvir and simeprevir, 76.0% (95% CI: 54.4-89.3) in those treated with sofosbuvir and daclatasvir, and 83.0% (95% CI: 73.4-89.6) in those treated with sofosbuvir and ledipasvir. The reasons for the choice of the regimens in the original investigations are unknown, but appeared to be dependent on when the various direct acting antiviral drugs were made available to physicians. On the Italian market, the combination of sofosbuvir and simeprevir was licensed first, followed by sofosbuvir with daclatasvir, and then by sofosbuvir and ledipasvir. Because these regimens were not randomised in the original investigations, we cannot compare their respective efficacies. However, we note that there was a 17% difference in SVR12 rates between sofosbuvir/simeprevir and sofosbuvir/ledipasvir, so a formal clinical trial comparing these therapeutic schedules is urgently required. In the meanwhile, the data presented here indicate that patients with Child C cirrhosis should be treated with sofosbuvir and ledipasvir, irrespective of ribavirin, for 12 weeks.
A further argument against treating these patients concerns the long-term benefit of therapy, as antiviral treatment in end-stage liver disease might be futile and only marginally affect prognosis. After successful therapy, the MELD score will improve in one-third of patients with cirrhosis, deteriorate in one-third and remain stable in one-third. 27 Of note, in the present investigation, an improvement of ≥2 points in the MELD score was seen in 61.1% of the Child C patients during follow-up. Unfortunately, the MELD score was only available for 103 of the 228 treated Child C patients, but the percentage of patients with an improved MELD score was remarkable. The difference seen between our data and previous studies on post-treatment benefit in patients with decompensated cirrhosis 22, 23 may be partially be due to the characteristics of the investigated patients: our survey was restricted to Child C patients, while in previous studies the majority of cases had Child B cirrhosis. About 50% of our patients with cirrhosis presented with a MELD score >15 at baseline, and the higher the MELD scores at baseline the more likely an improvement is seen at the post-treatment evaluation. Our investigation may have some limitations. Although the present collection represents the largest series to date of patients with Child C cirrhosis, in several sub-analyses the size of the investigated cohort limited our ability to draw conclusions. For instance, we cannot compare the different regimens because the reasons for choosing the regimen are not known: about three quarters of the patients received a combination of sofosbuvir with ledipasvir, and only a minority the other three currently available regimens. A second issue is that the patients included in the three largest studies 12, 13, 19 had an upper age limit of 63 years, so we do not have sufficient evidence to recommend treatment for older subjects. We tried to retrieve information on safety of the new antivirals administered to Child C patients, being aware of reports on the risk of hepatic decompensation following this therapy. 28, 29 In 2015, the FDA issued a warning against the administration of the new antivirals in patients with Child B and C cirrhosis, based on 26 cases of worsening liver failure. 30 Unfortunately, data on the safety of antiviral treatments and mortality during therapy in Child C patients in the original studies could not been analysed, as this information could not be extracted from the information from entire populations. Nutt et al. have reported that the overall incidence of hepatic decompensation in patients with cirrhosis treated with the newer direct antivirals was higher in those treated with sofosbuvir/simeprevir than in those treated with sofosbuvir/ledispavir. 31 We acknowledge this lack of data as a major limitation of the present investigation. Finally, the majority of treated patients in this analysis were infected with HCV genotype 1 and so the results refer to this subset of patients but may not apply to HCV genotypes 3 and 4. Despite these concerns, the overall SVR12 rates in this study are reassuring for patients with Child C cirrhosis.
In conclusion, the outcomes of the studies analysed in this review provide evidence for the effectiveness of the new interferon-free regimens for patients with Child C cirrhosis: their efficacy together with the remarkable improvement in post-treatment MELD scores indicate this subgroup of patients with severely impaired liver function should be treated. There is an urgent need to conduct a formal observational trial to evaluate the efficacy, safety and post-treatment outcome of the new protease inhibitors in patients with Child C cirrhosis.
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